Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT (Alt28； SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； (b) a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR (Alt34A； SEQ ID NO: 107) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； (d) a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ (Alt13A； SEQ ID NO: 83) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； (e) a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD (Alt01A； SEQ ID NO: 60) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK (Alt06； SEQ ID NO: 72) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； (g) a polypeptide comprising the amino acid sequence of DITYVATATLPNYCR (SEQ ID NO: 111) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； and (h) a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET (Alt14； SEQ ID NO: 84) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof； wherein a T cell epitope-containing variant sequence of a
